Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07179575

Study of LW231 in Participants With Chronic Hepatitis B

Conditions: Chronic HBV Infection

Sex: All

Ages: 18 Years – 60 Years

Healthy volunteers: No

Phase: PHASE1, PHASE2

Enrollment: 270

Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd.

Location: The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou Zhejiang

Summary

This is a Phase Ib/II, multicenter, randomized, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of LW231 in participants with chronic hepatitis B virus (HBV) infection. The trial will include multiple-dose regimens of LW231 and assess LW231 in combination with NUCs.

Eligibility Criteria

Inclusion Criteria: * Part 1: treatment-naïve and currently not treated subjects: LLOQ\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07179575). StuddyBuddy aggregates publicly available trial information.